The team set out to explore cancer drivers that allow NUT midline carcinoma — a rare, aggressive cancer that can arise in multiple organs — to become impervious to drugs. Their results may apply to several forms of cancer fueled by the same mutated driver gene, and their approach may be applicable to other types of cancer whose genomes have been sequenced.